KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 50 filers reported holding KEROS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,108 | -17.7% | 11,233 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $435,310 | +9.8% | 10,834 | +16.7% | 0.00% | 0.0% |
| Q1 2023 | $396,555 | -9.3% | 9,287 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $437,078 | +36.2% | 9,102 | +6.6% | 0.00% | +50.0% |
| Q3 2022 | $321,000 | +47.9% | 8,542 | +8.7% | 0.00% | +100.0% |
| Q2 2022 | $217,000 | -48.5% | 7,858 | +1.4% | 0.00% | -50.0% |
| Q1 2022 | $421,000 | -13.2% | 7,748 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $485,000 | +43.5% | 8,293 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $338,000 | -8.9% | 8,541 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $371,000 | -22.1% | 8,744 | +13.1% | 0.00% | -50.0% |
| Q1 2021 | $476,000 | -11.0% | 7,731 | +2.0% | 0.00% | 0.0% |
| Q4 2020 | $535,000 | +232.3% | 7,581 | +82.0% | 0.00% | +100.0% |
| Q3 2020 | $161,000 | +0.6% | 4,165 | -2.3% | 0.00% | 0.0% |
| Q2 2020 | $160,000 | – | 4,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |